Vol 26 (2023): Continuous Publishing
Other materials agreed with the Editors
Published online: 2023-12-28

open access

Page views 448
Article views/downloads 195
Get Citation

Connect on Social Media

Connect on Social Media

Registry of nuclear medicine procedures in cardiology in Poland in 2019–2021

Anna Teresińska1, Leszek Królicki2
Pubmed: 38153157
Nucl. Med. Rev 2023;26:158-164.

Abstract

Background: The purpose of the study was to present the cardiological procedures performed and scintigraphic devices used in Poland in 2019–2021 — based on the results of a nationwide survey.

Material and methods: Forty-three (100%) institutions performing scintigraphic cardiology tests responded to the survey: 29 classic nuclear medicine centers (NM), 4 PET centers, and 10 institutions performing NM and PET examinations.

Results: In 2021, 51 SPECT devices (including 5 dedicated cardiocentric semiconductor cameras, 12 SPECT gamma cameras, and 39 hybrid SPECT/CT devices) and 15 PET devices (14 PET/CT and 1 PET/MR) were used for cardiological examinations. The total number of cardiological SPECT and PET examinations has reached 33,107; PET shares 0.8%. The most frequently performed NM cardiological examination in 2019–2021 was myocardial perfusion scintigraphy (98–99% of all tests). NM cardiac amyloidosis studies accounted for less than 1% of all studies, and diagnostics of inflammation in the chest using labeled leukocytes — for less than 0.5%. The most frequently performed cardiological heart examination using the PET technique was the diagnostics of inflammation in the chest (166 of 269 examinations, i.e. 61.7%, in 2021), followed by the assessment of cardiac viability (46 examinations, i.e. 17.1%).

Conclusions: In Poland, in 2021, cardiac scintigraphy was performed in 39 classic nuclear medicine centers and 14 PET centers, using modern equipment, in approximately 1/1000 inhabitants per year. Polish nuclear cardiology is based on classical nuclear medicine. Almost 99% of the tests are stress and rest myocardial perfusion studies. PET has limited practical use (< 1% of cardiac studies).

Article available in PDF format

View PDF Download PDF file

References

  1. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
  2. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
  3. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. The Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC). Eur Heart J. 2021; 42(6): 563–645.
  4. Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022; 43(39): 3826–3924.
  5. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2022; 43(40): 3997–4126.
  6. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022; 43(41): 4229–4361.
  7. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM). Eur Heart J. 2023; 44(39): 3948–4042.
  8. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023; 44(37): 3503–3626.
  9. Verberne HJ, Acampa W, Anagnostopoulos C, et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. Eur J Nucl Med Mol Imaging. 2015; 42(12): 1929–1940.
  10. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016; 133(24): 2404–2412.
  11. SNC and EANM cardiac amyloidosis practice points. 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) and 99mTechnetium-hydroxymethylene diphosphonate (HMDP) Imaging for Transthyretin Cardiac Amyloidosis. ASNC 2019. https://www.eanm.org/content-eanm/uploads/2019/10/19110-ASNC-AND-EANM-Amyloidosis-Practice-Points-WEB.pdf (14.12.2023).
  12. ASNC cardiac amyloidosis practice points. 99mTechnetium-Pyrophosphate Imaging for Transthyretin Cardiac Amyloidosis. ASNC 2019. https://www.asnc.org/Files/Amyloid/ASNC%20Practice%20Point-99mTechnetium-Pyrophosphate.2019.pdf (14.12.2023).
  13. Królicki L, Teresińska A. Stan obecny i perspektywy rozwoju medycyny nuklearnej w Polsce. Problemy Medycyny Nuklearnej. 2001; 15(29): 5–12.
  14. Tillmanns C, Watkins H, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35(39): 2733–2779.